STAAR Surgical Company (STAA:NASDAQ) closed at $21.61 on October 21, 2026, down 3.18% on the day. The stock trades 39.8% below its 52-week high of $35.87 and 38.6% above its 52-week low of $15.59. Over the past year, it lost 13.2%. STAAR Surgical Company is part of the Health Care sector (Ophthalmic Goods).
In 252 trading sessions since October 21, 2025, STAA closed higher on 121 days (48%). Its best day was April 9, 2026 (+20.74%) and its worst was July 20, 2026 (-9.34%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 4 times.
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices; and manufactures AquaFlow devices for the treatment of glaucoma. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Afinity, and AquaFLOW...
Find more stocks like STAA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.